News
EOLS
11.39
-0.96%
-0.11
3 Top Stocks to Invest in for Amazing Earnings Acceleration
NASDAQ · 8h ago
Notable Wednesday Option Activity: F, EOLS, RCL
NASDAQ · 1d ago
Weekly Report: what happened at EOLS last week (0415-0419)?
Weekly Report · 3d ago
Evolus Announces Publication Of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines. Data showed duration effect of 26 weeks, or 6 months, based on a 1-point Glabellar Line Scale improvement. Jeuveau® is approved for sale in the U.S. And Australia.
Benzinga · 04/17 20:13
AbbVie working with FDA after reports of fake Botox versions
Seeking Alpha · 04/16 14:47
Weekly Report: what happened at EOLS last week (0408-0412)?
Weekly Report · 04/15 10:54
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. Grants stock options to 10 newly hired non-executive employees of the company. The stock options have a 10-year term and vest over 4 years. Evolus is a performance beauty company with a focus on building an aesthetic portfolio of consumer brands.
Barchart · 04/12 15:05
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)
TipRanks · 04/10 11:00
Weekly Report: what happened at EOLS last week (0401-0405)?
Weekly Report · 04/08 10:58
Evolus Inc Announces Strategic Board Renewal Plans
TipRanks · 04/03 20:43
Weekly Report: what happened at EOLS last week (0325-0329)?
Weekly Report · 04/01 10:56
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Members of Evolus' management team will present at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024. The company's flagship product, Jeuveau, is the first and only neurotoxin dedicated exclusively to aesthetics. The investor conference will be held in New York.
Barchart · 03/26 07:00
Weekly Report: what happened at EOLS last week (0318-0322)?
Weekly Report · 03/25 10:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Biolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The company's market cap increased to $466.4 million. Terns Pharma shares rose 10.14% after their Q4 earnings came out today. Aptevo Therapeutics and Evolus also moved upwards.
Benzinga · 03/21 21:33
5 Stocks Hedge Funds Love and have Analysts Support
TipRanks · 03/21 11:34
Evolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth Investors
TipRanks · 03/21 05:59
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
Evolus raised $60m in its IPO in 2018. Its first and only commercial product, Jeuveau, was approved in the US and most European territories in 2019. Evolus has settled a lawsuit with AbbVie and is focused on taking on Botox in the commercial markets. Management has guided for over $250m revenues in 2024, and over $700m by 2028.
Seeking Alpha · 03/20 18:05
Weekly Report: what happened at EOLS last week (0311-0315)?
Weekly Report · 03/18 10:57
Survey finds GLP-1 users more inclined to get aesthetic procedures
Seeking Alpha · 03/17 21:09
4 Stocks to Buy for Attractive Earnings Acceleration
NASDAQ · 03/15 10:13
More
Webull provides a variety of real-time EOLS stock news. You can receive the latest news about Evolus through multiple platforms. This information may help you make smarter investment decisions.
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.